Hepatoprotective effect of ethanolic extract of Curcuma longa on thioacetamide induced liver cirrhosis in rats
© Salama et al.; licensee BioMed Central Ltd. 2013
Received: 24 July 2012
Accepted: 20 February 2013
Published: 5 March 2013
Hepatology research has focused on developing traditional therapies as pharmacological medicines to treat liver cirrhosis. Thus, this study evaluated mechanisms of the hepatoprotective activity of Curcuma longa rhizome ethanolic extract (CLRE) on thioacetamide-induced liver cirrhosis in rats.
The hepatoprotective effect of CLRE was measured in a rat model of thioacetamide-induced liver cirrhosis over 8 weeks. Hepatic cytochrome P450 2E1 and serum levels of TGF-β1 and TNF-α were evaluated. Oxidative stress was measured by malondialdehyde, urinary 8-hydroxyguanosine and nitrotyrosine levels. The protective activity of CLRE free-radical scavenging mechanisms were evaluated through antioxidant enzymes. Protein expression of pro-apoptotic Bax and anti-apoptotic Bcl-2 proteins in animal blood sera was studied and confirmed by immunohistochemistry of Bax, Bcl2 proteins and proliferating cell nuclear antigen.
Histopathology, immunohistochemistry and liver biochemistry were significantly lower in the Curcuma longa-treated groups compared with controls. CLRE induced apoptosis, inhibited hepatocytes proliferation but had no effect on hepatic CYP2E1 levels.
The progression of liver cirrhosis could be inhibited by the antioxidant and anti-inflammatory activities of CLRE and the normal status of the liver could be preserved.
KeywordsCurcuma longa Antioxidant enzymes Cytochrome P450 2E1 (CYP2E1) Histology Oxidative stress Immunohistochemistry
Cirrhosis is the damage of liver cells and their gradual replacement with scar tissue that impairs blood flow through the liver causing hepatocyte death and loss of liver function . Hepatic fibrosis occurs in response to liver damage and regenerates apoptotic cells after repeated injury . This inflammatory response is accompanied by limited deposition of extra cellular matrix (ECM), so that if the regeneration of dying cells fails during persistent liver injury, hepatocytes are replaced by abundant ECM, including fibrillar collagen, depending on the origin of injury . Treatment options for common liver disease such as cirrhosis, fatty liver and chronic hepatitis are problematic. The effectiveness of treatments such as interferons, colchicines, penicillamine and corticosteroids are inconsistent at best and the incidence of side-effects profound . Because of the role of oxidative stress in liver cirrhosis, antioxidants have been proposed as a treatment for cirrhosis . Several studies have demonstrated the protective effects of antioxidants against induced liver injury by reducing oxidative stress in cells [6, 7]. A number of herbals show promising activity, including Silymarin for liver cirrhosis, glycyrrhizin for chronic viral hepatitis, and herbal combinations from China and Japan that have been proven for treatment of liver diseases . Silymarin, a reference drug, is a flavonolignan from ″milk thistle″ Silybum marianum, and widely used for the treatment of hepatitis and liver cirrhosis .
Curcuma longa is a rhizomatous perennial herb that belongs to the family Zingiberaceae, native to South Asia and is commonly known as turmeric. In Malaysia, commonly known as Kunyit, turmeric plant is a popular ingredient for preparing culinary dishes. In addition, it is used as herbal remedy due to the prevalent belief that the plant has medical properties. In folk medicine, the rhizome juice from C. longa is used in the treatment of many diseases such as anthelmintic, asthma, gonorrhea and urinary, and its essential oil is used in the treatment of carminative, stomachic and tonic . In traditional medicine, several plants and herbs have been used experimentally to treat liver disorders, including liver cirrhosis, [11, 12]. C. longa possesses antioxidant , anti-tumor , antimicrobial , anti-inflammatory , wound healing , and gastroprotective activities . The previous studies have also shown that the aqueous extract of C. longa has hepatoprotective activity against carbon tetrachloride toxicity . In this study, we assessed the hepatoprotective effect of the ethanolic extract of C. longa rhizomes against TAA-induced liver cirrhosis in Sprague Dawley rats.
Preparation of CLRE
C. longa rhizomes were obtained from Ethno Company, Kuala Lumpur, Malaysia and identified by comparison with the voucher specimen (KLU41829) deposited at the Herbarium of Rimba Ilmu, Institute of Biological Sciences, University of Malaya, Kula Lumpur, Malaysia The rhizomes were cleaned, dried, ground, weighed, and homogenized in 95% ethanol at a ratio of 1:10 of plant to ethanol and left to soak for 3 days at 25°C with occasional shaking and stirring. The mixture was then filtered and the resulting liquid was concentrated under reduced pressure at 45°C in an EYELA rotary evaporator to yield a dark gummy-yellow extract (7%, w/w). The concentrated extract was then kept in the incubator at 45°C for 3 days to evaporate the ethanol residue yielding the crude rhizome extract. Extracts were then dissolved in 10% Tween-20 before being orally administrated to animals in concentrations of 250 and 500 mg/kg body weight (5ml/kg body weight).
Total phenol content (TPC) of CLRE
The Total Phenol content (TPC) of the CLRE extract was determined by the Folin Denis calorimetric method using Folin-Ciocalteau reagent (Merck, Darmstadt, Germany) in gallic acid equivalent in mg (GAE/mg extract) . CLRE (1 mg) was first dissolved in 1 mL dimethyl sulfoxide (DMSO). Next, 20 μL of the extract was added into 100 μL of Folin-Ciocalteau reagent, and the resulting mixture was incubated in the dark for 3 min. Then, 100 μL of sodium carbonate (1 g/10 mL) solution was added to the mixture, and mixed thoroughly. The final mixture was kept in the dark for 1 h and its absorbance (750 nm wavelength) was read by an ELISA reader (UV 1601 spectrophotometer, Shimadzu, Japan). All procedures were carried out in triplicate. Linear standard curves were produced by serial dilution of gallic acid (1 mg/mL DMSO) and the absorbance was read at 750 nm.
Ferric reducing anti-oxidant power of CLRE
The ferric reducing anti-oxidant power (FRAP) of CLRE was assayed according to the previously described method  with slight modification. FRAP reagent was prepared by adding 300 mM acetate buffer (3.1 mg sodium acetate/mL, pH 3.6) to 10 mM 2,4,6-tripyridyl-S-triazine (TPTZ) solution (Merck, USA) and 20 mM FeCl3.H2O (5.4 mg/mL). Ten μL of 1 mg/mL of CLRE (equivalent to 500 mg/kg dose administrated daily to animals) and the standards gallic acid, quercetin, ascorbic acid, retin, trolox and 2,6-di-tert-butyl-4 methyl phenyl (BHT) were each sampled with 10 μL of 0.1 mg/mL Silymarin (equivalent to 50 mg/kg dose administrated daily to animals) and added to 290 μL of TPTZ reagent in triplicate wells. Absorbance was read at 593 nm using an ELISA reader (Shimadzu, Japan) every 4 min for 2 h.
Sixty-six healthy Sprague Dawley rats (180-250 g) were used in the experiments. All rats were kept in wire-bottomed cages at 25 ± 2°C, given tap water and standard pellet diet and exposed to a 12 h:12 h light–dark cycle at 50–60% humidity in an animal room. Throughout the experiments, all animals received human care according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals” prepared by the National Academy of Sciences and published by the national Institute of health. The study was approved by the Ethics Committee for Animal Experimentation, Faculty of Medicine, University of Malaya, Malaysia PM/28/08/2009/MAA.
Acute toxicity study
Eighteen males and eighteen females healthy rats were assigned equally into 3 groups of 6 rats: vehicle (receiving 10% Tween-20 w/v, 5 mL/kg); or treated with 2 g/kg or 5 g/kg of CLRE preparation, respectively. The animals were fasted overnight but water prior to dosing. Food was withheld for a further 3-4 h after dosing. The animals were observed for 30 min and at 2, 4, 8, 24 and 48 h after administration for the onset of clinical or toxicological symptoms. The animals were sacrificed on the 15th day. Histological and serum biochemical parameters were determined using standard methods .
Induction of liver cirrhosis in rats
Thioacetamide (TAA, CH3-C(S)NH2) is a hepatotoxin and hepatocarcinogenic when administered in the diet of experimental animals, and is widely used as a model of acute and chronic liver disease  Briefly, after administration of TAA in the diet, it is converted to TAA-S-oxide (TASO) by hepatic microsomal cytochrome P450 2E1 (CYP2E1), then transformed to toxic thioacetamide S-dioxide (TASO2) . TASO2 damages biomolecules of the liver leading to cirrhosis .
Male animals were randomly divided into 5 groups of 6 rats. Rats of Group 1 (normal control group) were orally administrated with 10% Tween-20 (5 mL/kg) daily and intraperitoneally (ip) injected with sterile distilled water (1 mg/kg) thrice weekly. Groups 2–5 were administered with TAA by intraperitoneal injection (200 mg/kg/mL) three times a week to induce liver cirrhosis. Constant exposure of this concentration of TAA induces pathological changes in the liver comparable to the etiology of cirrhosis in humans . The stock solution was prepared (5 g/L) by dissolving TAA crystals (Sigma-Aldrich, USA) in sterile distilled water and stirred till completely dissolved . Rats of Group 2 (cirrhosis control group) were orally administrated with 10% Tween-20 (5 mL/kg) daily. Rats of Group 3 (Silymarin-treated group) were orally administrated with Silymarin (50 mg/kg) daily. Silymarin (International Laboratory, USA) was properly dissolved in 10% Tween-20 and used as a standard drug. Rats of Groups 4 and 5 (treatment groups) were orally administrated with CLRE at daily doses of 250 mg/kg and 500 mg/kg, respectively. The treatment procedure was considered an 8-week period due to the preventive nature of the experiment (Silymarin and CLRE), protecting the liver from further damage. At the end of the 8 weeks, the rats were fasted for 24 h after the last treatment and perfused under ketamine (30 mg/kg, 100 mg/mL) and xylazil (3 mg/kg, 100 mg/mL) anesthesia . Blood was withdrawn through the jugular vein and collected for prothrombin time ratio evaluation, biochemical examinations, cytokines and apoptotic proteins assessment. Liver tissues were excised, washed with ice cold normal saline, blotted on filter paper and weighed. The tissues were examined thoroughly for gross cirrhosis. They were prepared for evaluation of the oxidative damages and histopathology assessment. Liver tissues were homogenized (10% w/v) in 50 mM cold potassium phosphate buffer (pH 7.4) using a Teflon homogenizer (Polytron, Heidolph RZR 1, Germany). Then the tissue homogenates were centrifuged at 3500 rpm for 15 min at 4°C in a centrifuge (Heraeus, Germany). The supernatant of each sample was collected and frozen in aliquots for later use.
Blood samples from animals were collected in sodium citrate tubes for determining prothrombin time or in gel-activated tubes for the assessment of specific liver markers. The gel-activated tubes were allowed to clot, then centrifuged at 3400 rpm for 10 min at 4°C. The serum samples were collected for measuring liver markers, alkaline phosphatase (AP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total protein, albumen and bilirubin. The markers were assayed with a spectrophotometer at Central Diagnostic Laboratory of the Medical Center of University Malaya.
Assessment of hepatic CYP2E1 levels
The level of CYP2E1 in the liver tissue homogenate of all rats was evaluated by following the instructions of a sandwich enzyme immunoassay (Uscn Life Science, China). Briefly, 100 μL of the sample was incubated with pre-coated capture antibody specific to CYP2E1 in a 96-well plate for 2 h at 37°C. After mild rinsing, the sample was incubated for 1 h at 37°C with 100 μL of biotin-conjugated secondary antibody followed by three times washing by 350 μL washing buffer. Streptavidin-Horse radish peroxidase (HRP) was added (100 μl) to the sample and incubated for 30 min at 37°C followed by 5 repeated washes. Tetramethylbenzidine (TMB) was added (90 μL) to the sample as a colorimetric reagent and incubated for 20 min, stopped by H2SO4 (50 μL) and the absorbance was read at 450 nm.
Evaluation of oxidative stress markers
8-hydroxy-2-deoxyguanosine (8-OH-dG) is a product of DNA oxidative damage through reactive oxygen species (ROS) and serves as an established oxidative stress marker . To evaluate the DNA oxidative damage, urine samples from all animals were collected 24 h before sacrifice and stored (-80°C). The levels of 8-OH-dG were measure according to the instructions of the manufacturer (Genox KOG-HS10E, USA). In brief, in a 96-well microtiter plate, pre-coated with monoclonal antibody specific for 8-OH-dG, a urine sample (50 μL) was incubated at 4°C overnight. The plate was then washed (5 times) with concentrated buffered saline (pH=7.4). 100 μL of biotinylated secondary antibody was added to the sample and incubated for 1 h at room temperature followed by a 3-time rinsing. The chromatic solution tetramethylbenzidine (TMB) was added (100 μL) and incubated at room temperature for 15 min in dark. The reaction terminating solution (1M phosphoric acid) was added (100 μL) and the plate was read with a spectrophotometer at 450 nm.
Nitrotyrosine, a marker for protein oxidation  was assessed in liver tissue homogenate of all animals by ELISA according to the manufacturer protocol (MyBiosource, USA). Succinctly, 100 μL of the sample was incubated with monoclonal Nitrotyrosine-HRP conjugate in a microtiter plate. After 1 h of incubation, the plate was washed 5 times by 350 μL wash solution. Then substrate specific to HRP enzyme was added (100 μL) to the sample followed by 50 μL stop solution and the intensity of the produced colour was measured with a spectrophotometer at 450 nm.
Malondialdehyde (MDA) levels were measured in the liver tissue homogenate of all experimental groups as a measure for lipid peroxidation using thiobarbituric acid according to the manufacturer’s instructions (Cayman, Sigma). Ready to use SDS solution was added (100 μL) to the samples/standard (100 μL). Then 4 mL of the colour reagent were added to the mixture. Samples and standard solutions vials were immersed in boiling water for 1 h. The reaction was stopped when they were incubation in an ice bath for 10 min. All vials were then centrifuged at 1600 × g for 10 min at 4°C. A set of duplicated samples or standards were loaded into 96-well plate, and their absorbance were read at 532 nm by a spectrophotometer.
Antioxidant enzyme assessment
Superoxide dismutase (SOD) and catalase (CAT) enzymes were measured for each liver tissue homogenate (Cayman, USA). SOD activity was evaluated by tetrazolium salt detecting superoxide radicals produced by the action of xanthine oxidase on hypxanthine. Bovine erythrocyte SOD was used to represent SOD standard curve. 200 μL of tetrazolium salt solution was added to 10 μL standards or samples followed by fast addition of 20 μL of xanthine oxidase to initiate the reaction. The plate was covered and incubated for 20 min on a plate shaker (Barnstead Dubuque, USA) and the reading of the spectrophotometer was recorded at 450 nm. CAT activity was evaluated by the chromagen, 4-amino-3 hydrazino-5-mercapto-1,2,4-triazole which measures the formaldehyde produced by the reaction of CAT enzyme with methanol in the presence of H2O2. The standard curve was obtained by catalase formaldehyde standard. Assay buffer (100 μL) and methanol (30 μL) were added to the standards or samples (20 μL) and the reaction was initiated when 20 μL of H2O2 was added. The plate was incubated in dark at room temperature for 20 min. Then Potassium Phosphate buffer (30 μL) was added to terminate the reaction. Chromagen was added (30 μL) and the plate was incubated on a shaker at room temperature in the dark. After 10 min, catalase potassium periodate was added (10 μL) and the plate was covered and left on the shaker at room temperature for 5 min. The absorbance was measure with a spectrophotometer at 540 nm.
Assessment of cytokines
Blood samples from each group was centrifuged at 3500 rpm and the sera were stored (-80°C) in aliquots for assessment of transforming growth factor-beta (TGF-β), a fibrogenesis-driving cytokine, and tumornecrosisfactor-alpha (TNF-α), according to the manufacturers’ instructions (Abnova, USA). Briefly, the captured antibody was diluted with the sample buffer provided and added onto 96-plate pre-coated with anti-rat antibody specific to TGF-β or TNF-α. After the recommended incubation period, biotinylated anti-rat specific antibody was added and left incubated at 37°C in the dark. Then the samples and the standards were incubated with streptavidin-HRP conjugate which was washed with the washing buffer. The wells were then incubated with the colorimetric reagent TMB and the reaction was stopped so that to read the absorbance at 450 nm. The concentrations were calculated by the optical density measurements from the obtained standard curve.
Pro-apoptotic Bax and anti-apoptotic Bcl-2 assessment
Rat Bax ELISA kit and Rat Bcl-2 ELISA kit (Uscn Life Science, China) were used to evaluate the expression of Bax and Bcl-2 proteins in the rat sera. Prior to use, sera samples stored at -80°C were warmed up in 37°C bath and then protein concentration in the samples was measured. The absorbance was read at 450 nm and the concentration ratio of Bax/ Bcl-2 was then calculated accordingly.
Liver samples were fixed in 10% buffered formaldehyde, processed by an automated tissue processing machine followed by paraffin wax embedding. Sections (5 μm in thickness) were prepared and stained with hematoxylin and eosin (H&E) for histopathological examination of the liver tissue. Staining with Masson’s Trichrome (Sigma, USA) was used as a marker of fibrosis to assess the degree of fibrosis by identifying collagen fibers in liver tissues. All the slides were examined under a light microscope and images were captured with a Nikon microscope (Y-THS, Japan).
Liver tissue sections were heated at 60°C for 25 min in an oven (Venticell, MMM, Einrichtungen. Germany) and then deparaffinized in xylene and rehydrated using graded alcohol. The process of antigen retrieval was performed in 10 mM sodium citrate buffer boiled in a microwave. Immunohistochemistry staining steps were performed following the manufacturer’s instructions (DakoCytomation, USA). In brief, endogenous peroxidase was blocked using 0.03% hydrogen peroxide sodium azide for 5 min. Tissue sections were washed gently with wash buffer and then incubated with Bcl-2–associated X protein (Bax) (1:500), Proliferating Cell Nuclear Antigen (PCNA) (1:200) and anti-apoptotic protein Bcl2 (1:50) biotinylated primary antibodies for 15 min. Sections were gently washed with wash buffer and kept in the buffer bath in a humid chamber. A sufficient amount of streptavidin-HRP was then added and incubated for 15 min followed by washing. Diaminobenzidine-substrate chromagen was added to the sections and incubated for over 7 min followed by washing and counterstaining with hematoxylin for 5 sec. The sections were then dipped in weak ammonia (0.037 M/L) 10 times, washed and cover slipped. Positive antigens stained brown under light microscopy.
Statistical analysis of the results was performed using one-way ANOVA (Tukey Post-Hoc Test analysis) using SPSS version 18 (SPSS Inc, USA). All values were reported as mean ± SEM and a value of P< 0.05 was considered statistically.
TPC and FRAP results
CLRE does not induce acute toxicity
Effect of CLRE on renal function tests in rats
Vehicle (10% Tween-20)
139.79 ± 1.34
4.87 ± 0.47
104.81 ± 1.42
4.69 ± 0.42
40.10 ± 2.63
Low dose CLRE (2 g/kg)
143.31 ± 2.11
5.14 ± 0.39
103.46 ± 2.04
4.97 ± 0.58
39.00 ± 2.71
High dose CLRE (5 g/kg)
140.67 ± 2.67
5.09 ± 0.40
103.70 ± 1.52
5.27 ± 0.52
38.82 ± 3.14
Effect of CLRE on liver function tests in rats
Vehicle (10% Tween 20)
68.33 ± 1.71
11.78 ± 0.76
1.74 ± 0.13
72.75 ± 5.53
37.65 ± 2.66
53.58 ± 5.20
4.50 ± 0.19
Low dose CLRE (2 g/kg)
71.17 ± 1.28
12.76 ± 0.58
2.15 ± 0.16
66.90 ± 5.40
39.17 ± 3.16
62.48 ± 2.63
4.08 ± 0..45
High dose CLRE (5 g/kg)
69.17 ± 1.85
12.26 ± 0.64
1.85 ± 0.46
70.08 ± 11.12
34.50 ± 2.91
55.17 ± 4.83
4.67 ± 0.33
Effect of CLRE on liver cirrhosis
Effect of CLRE on liver index measurements from rats at the end of 8 weeks study
Body weight (g)
Liver weight (g)
Liver weight × 100/body weight
341.33 ± 6.18
8.43 ± 0.34
2.47 ± 0.06
216.83 ± 10.96
10.13 ± 0.54
4.70 ± 0.22**
336 ± 9.187
9.12 ± 0.34
2.72 ± 0.14*
Low dose CLRE-treated rats (250 mg/kg)
249.17 ± 14.89
8.80 ± 0.29
3.58 ± 0.19*
High dose CLRE-treated rats (500 mg/kg)
351 ± 19.73
9.48 ± 0.19
2.74 ± 0.15*
Specific liver markers and total protein, albumen and Bilirubin
Hepatic CYP2E1 levels
Oxidative stress markers
Effect of CLRE on OHdG, Nitrotyrosine and MDA from rats at the end of 8 weeks study
MDA (nM/mg protein)
2.17 ± 0.33
1.06 ± 0.07
2.17 ± 0.33
5.40 ± 0.34**
3.87 ± 0.13**
5.40 ± 0.34**
2.80 ± 0.15*
1.67 ± 0.07*
2.80 ± 0.15*
Low Dose CLRE-treated rats (250 mg/kg)
2.83 ± 0.33*
1.40 ± 0.20*
2.83 ± 0.33*
High Dose CLRE-treated rats (500 mg/kg)
2.37 ± 0.88*
1.33 ± 0.13*
2.37 ± 0.88*
Hepatocellular antioxidant enzymes
Pro-apoptotic Bax and anti-apoptotic Bcl-2 assessment
Gross anatomy and histopathology
Masson’s Trichrome staining
Immunohistochemistry of Bax, Bcl2 and PCNA
Prescription drugs with side effects have become widely used in modern life and as a result, liver cirrhosis has become a serious health problem. Consequently, the current study focused on finding new therapeutic solutions to minimize liver damage . Natural products, especially plants in folk medicine with an anecdotal history of positive effects against liver diseases or other organs, are considered an alternative therapeutic approach . In the present research, the ethanol extract of C. longa rhizomes was examined as a promising therapy for treating liver cirrhosis. This study evaluated the toxicity of CLRE along with the clinical biochemistry values, which confirmed by the biochemical results (Tables 1 and 2). In addition, histological examination showed no significant pathological abnormalities in both the liver and the kidney, even at high doses of 5 g/kg (Figure 2). The hepatoprotective effects of CLRE on the development of liver cirrhosis, induced by prolonged exposure to TAA (200 mg/kg ) were assessed though this study. The protocol induced cirrhosis with similar pathology and etiology pattern to the human liver cirrhosis with the same biochemical values for typical human cirrhosis markers . The results were reconfirmed quantitatively by measurement of the liver index of the cirrhotic animals (Table 3), the biochemical imbalances in the liver markers (Figures 3 and 5) and the altered total protein content, albumen and bilirubin levels (Figure 4). A marked reduction of plasma total protein levels were observed in the cirrhosis control Group 2 compared with the normal healthy animals of Group 1 (Figure 4), as described in other TAA intoxication models . Hepatic factors (AP, ALT, and AST) were significantly increased in the cirrhosis control rats, as previously described . CLRE-treatment caused significant recovery of these enzymatic activities (Figure 3). Parallel findings were also previously reported .
TAA has been used to induce hepatotoxicity in the experimental animals to produce various grades of liver damage including nodular cirrhosis, liver cell proliferation, production of pseudolobules, and parenchymal cell necrosis . It is a potent hepatotoxic agent metabolized by CYP2E1 enzymes present in liver microsomes and is converted to a toxic reactive intermediate called thioacetamide by oxidation . Here, we measured the levels of CYP2E1 in the liver tissues of all animals and found that CLRE extract administration was not as effective as Silymarin (Figure 6) in terms of hepatic CYP2E1 inhibition and attenuating drug-induced hepatotoxicity . Parallel findings reported that curcumin, the active ingredient of C. longa rhizomes and constitutes 2.5-6% of the plant rhizome constituents  had no significant effect on CYP2E1 [30, 40].
The development of liver cirrhosis by TAA was reported to be multifaceted involving multiple mechanisms . For instance, TAA induces hepatocyte damage via its metabolite, TASO2, which covalently binds to macromolecules of hepatocytes causing DNA damage, protein oxidation and lipid peroxidation of the cell membrane biomolecules [25, 42]. In the present study, we evaluated the oxidative stress markers and observed that the level of damage to liver cells due to oxidative stress was very high in the cirrhosis rats of Group 2 as indicated by high levels of urine 8-OH-dG, nitrotyrosine and MDA (Table 4). However, the levels in low-dose and high dose CLRE-treated rats were encouragingly close to that of Silymarin-treated rats, supporting previous studies on the protective effect of C. longa against oxidative stress by down-regulation of ROS  by inhibiting DNA damage and attenuating protein and lipid oxidation of hepatocytes as indicated by low levels of urine 8-OH-dG, nitrotyrosine and MDA respectively in CLRE-treated animals.
Reduced hepatic antioxidant functions have also been suggested to be one mechanism of TAA-induced hepatotoxicity . Our results revealed that administration of CLRE to the cirrhotic rats significantly alleviated the TAA-suppressive effect on antioxidant enzymes SOD and CAT by maintaining the activity of these enzymes at higher levels (Figures 7 and 8). Optimizing the level of hepatocellular antioxidant enzymes led to removal of oxidative stress by scavenging the free radicals resulting from TAA-toxicity. Antioxidant activity of CLRE may be attributed to the antioxidant properties of phenol compound constituents which constitute 3-15% of rhizomes  and that TPC is equivalent to gallic acid (517.54 ± 0.049 mg GAE/mg extract). Toxins target metabolically active hepatocytes  leading to hepatocyte dysfunction and the release of ROS, and fibrogenic and inflammatory mediators. Several studies have suggested that part of hepatocellular injury induced by TAA is mediated through oxidative stress caused by the action of cytokines through lipid peroxidation . The free radicals resulting from TAA metabolism may activated myofibroblasts, that secrete fibrinogen and growth factors . TGF-β1, a prominent profibrogenic cytokine with antiproliferative effects that can up-regulate the deposition of ECM , was present at high levels in the cirrhosis rats of Group 2 compared with the other groups (Figure 9). In addition, the pro-inflammatory cytokine TNF-α  was elevated in the cirrhosis rats indicating a high inflammatory state in the cirrhotic liver. Low or high dose CLRE administration to the rats reduced the high levels of cytokines in their sera, supporting previous reports on the inhibitory effects of curcumin on the transcription of nuclear factor NF-κB binding activity, and TNF-α  and TGF-β1 expression .
Upon liver injury, hepatic stellate cells acquire a highly proliferative index producing fibrillar collagen within the injured liver . Our biochemical findings were supported by the gross and histopathological examinations of the rat liver tissues (Figures 10 and 11) showing that livers from CLRE-treated rats had nearly normal liver architecture. In addition, Masson’s Trichrome staining showed significant improvement in collagen synthesis upon administration of CLRE to the rats treated with TAA. This was probably due to the inhibitory effect of CLRE on hepatic stellate cell activation. These findings confirmed previous studies, demonstrating the attenuating effect of curcumin against liver fibrosis by inhibiting HSC activity . Curcumin, the most common antioxidant constituent of Curcuma longa rhizome extract, was reported to enhance apoptosis of damaged hepatocytes which might be the protective mechanism whereby curcumin down-regulated inflammatory effects and fibrogenesis of the liver .
A number of studies have focused on the molecular regulation of apoptosis. Over expression of the pro-apoptotic proteins Fas, FasL and Bax were reported in chronic hepatitis . Toxicity induced by TAA was found to be accompanied by elevation in Bax protein levels and reduction in the anti-apoptotic protein Bcl2 and its translocation into the mitochondria, causing apoptosis . In the current study, we observed significant increase in the serum level of Bax protein and decrease in Bcl-2 protein in silymarin-treated and CLRE- treated animals compared with the cirrhosis group animals. This was confirmed by the ratio Bax/Bcl-2 which was high in the treated groups compared with the cirrhosis group and the large number of Bax positive-stained hepatocytes together with few Bcl2 positive-stained hepatocytes both doses of CLRE-treated animals, and in Silymarin-treated animals compared with the cirrhosis Group (Figures 10, 11, 13A and 13B) indicating the susceptibility of these cells to apoptosis and the role of curcuminoids in inducing apoptosis . Furthermore, those animals on daily feeding with CLRE along with TAA injections thrice weekly for 8 weeks attenuated hepatocyte proliferation and regeneration as indicated by a significant decrease in PCNA positive-stained cells in the liver sections from the low dose and high dose-treated groups similar to that in the Silymarin-treated group (Figure 14) . These results were consistent with previous reports that curcumin the active ingredient of CLRE extract had inhibitory effect on hepatocyte proliferation . Treating the animals with CLRE extract inhibited the necrotic effect due to thioacetamide administration by modifying necrosis into apoptosis, which might be through cytochrome release from mitochondria and caspase activation . This modification in vivo would scale down the release of inflammatory mediators that would prevent progressive live damage. The ethanolic extract of C. longa rhizomes showed a significant hepatoprotective effect when orally administrated in doses of 250 mg/kg and 500 mg/kg, and the protective effect was dose-dependent. The main constituents of CLRE extract are the flavonoid curcumin and various volatile oils, including tumerone, atlantone, and zingiberene. The hepatoprotective effects of turmeric and curcumin might be due to direct antioxidant and free-radical scavenging mechanisms, as well as the ability to indirectly augment glutathione levels, thereby aiding in hepatic detoxification . The volatile oils and curcumin of C. longa exhibit potent anti-inflammatory effects .
In conclusion, our results demonstrated that the progression of TAA-induced liver cirrhosis could be prevented or reduced using the ethanol extract of C. longa rhizomes. The plant natural extract exerted its hepatoprotective effect by preventing the harmful cascade of events induced by TAA toxicity. This hepatoprotective capability of CLRE preserved the liver’s status quo in terms of its properties, functions and structure against toxins, and warranted further study to explore its pharmacologic potential in treating liver cirrhosis. In addition, Curcumin might be predominantly responsible for the hepatoprotective effect of CLRE rhizome extract. These findings would encourage further studies on the pharmacological significance of using plant extracts as alternative medicines for treating liver cirrhosis.
This study was financially supported by the University of Malaya through University Malaya Research Grant PV042-2011A and HIR Grant (F000009-21001). The authors are thankful to the staffs of Department of Molecular Medicine, and Clinical Diagnostic Laboratory of University Malaya.
- Wang S, Nagrath D: Liver Tissue Engineering. Biomaterials for Tissue Engineering Applications: A Review of the Past and Future Trends. 2010, 14: 389-Google Scholar
- Friedman SL, McQuaid KR, Grendell JH: Current diagnosis & treatment in gastroenterology. 2002, New York: Lang Medical Books/McGraw-HillGoogle Scholar
- O'Connell M, Rushworth S: Curcumin: potential for hepatic fibrosis therapy?. Br J Pharmacol. 2008, 153 (3): 403-405. 10.1038/sj.bjp.0707580.View ArticlePubMedGoogle Scholar
- Strader DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004, 39 (4): 1147-1171. 10.1002/hep.20119.View ArticlePubMedGoogle Scholar
- Loguercio C, Federico A: Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med. 2003, 34 (1): 1-10. 10.1016/S0891-5849(02)01167-X.View ArticlePubMedGoogle Scholar
- Bansal AK, Bansal M, Soni G, Bhatnagar D: Protective role of Vitamin E pre-treatment on nitrosodiethylamine induced oxidative stress in rat liver. Chem Biol Interact. 2005, 156 (2): 101-111. 10.1016/j.cbi.2005.08.001.View ArticlePubMedGoogle Scholar
- Cederbaum AI, Lu Y, Wu D: Role of oxidative stress in alcohol-induced liver injury. Arch Toxicol. 2009, 83 (6): 519-548. 10.1007/s00204-009-0432-0.View ArticlePubMedGoogle Scholar
- Stickel F, Schuppan D: Herbal medicine in the treatment of liver diseases. Dig Liver Dis. 2007, 39 (4): 293-304. 10.1016/j.dld.2006.11.004.View ArticlePubMedGoogle Scholar
- Dvorák Z, Kosina P, Walterová D, Simánek V, Bachleda P, Ulrichová J: Primary cultures of human hepatocytes as a tool in cytotoxicity studies: cell protection against model toxins by flavonolignans obtained from Silybum marianum. Toxicol Lett. 2003, 137 (3): 201-212. 10.1016/S0378-4274(02)00406-X.View ArticlePubMedGoogle Scholar
- Phansawan B, Poungbangpho S: Antioxidant capacities of Pueraria mirifica, Stevia rebaudiana Bertoni, Curcuma longa Linn., Andrographis paniculata (Burm. f.) Nees. and Cassia alata Linn. for the development of dietary supplement. Kasetsart J. 2007, 41 (3): 407-413.Google Scholar
- Alshawsh MA, Abdulla MA, Ismail S, Amin ZA: Hepatoprotective Effects of Orthosiphon stamineus Extract on Thioacetamide-Induced Liver Cirrhosis in Rats. Evid Based Complement Alternat Med. 2011, 2011: 1-6.View ArticleGoogle Scholar
- Kadir FA, Othman F, Abdulla MA, Hussan F, Hassandarvish P: Effect of Tinospora crispa on thioacetamide-induced liver cirrhosis in rats. Indian J Pharmacol. 2011, 43 (1): 64-10.4103/0253-7613.75673.View ArticlePubMedPubMed CentralGoogle Scholar
- Maizura M, Aminah A, Wan Aida W: Total phenolic content and antioxidant activity of kesum (Polygonum minus), ginger (Zingiber officinale) and turmeric (Curcuma longa) extract. Int Food Res J. 2011, 18: 526-531.Google Scholar
- Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB: Curcumin Potentiates Antitumor Activity of Gemcitabine in an Orthotopic Model of Pancreatic Cancer through Suppression of Proliferation, Angiogenesis, and Inhibition of Nuclear Factor-κB–Regulated Gene Products. Cancer Res. 2007, 67 (8): 3853-10.1158/0008-5472.CAN-06-4257.View ArticlePubMedGoogle Scholar
- Kim KJ, Yu HH, Cha JD, Seo SJ, Choi NY, You YO: Antibacterial activity of Curcuma longa L. against methicillin‐resistant Staphylococcus aureus. Phytother Res. 2005, 19 (7): 599-604. 10.1002/ptr.1660.View ArticlePubMedGoogle Scholar
- Kohli K, Ali J, Ansari M, Raheman Z: Curcumin: a natural antiinflammatory agent. Indian J Pharmacol. 2005, 37 (3): 141-147. 10.4103/0253-7613.16209.View ArticleGoogle Scholar
- Panchatcharam M, Miriyala S, Gayathri VS, Suguna L: Curcumin improves wound healing by modulating collagen and decreasing reactive oxygen species. Mol Cell Biochem. 2006, 290 (1): 87-96. 10.1007/s11010-006-9170-2.View ArticlePubMedGoogle Scholar
- Miriyala S, Panchatcharam M, Rengarajulu P: Cardioprotective effects of curcumin. The molecular targets and therapeutic uses of curcumin in health and disease. 2007, 595: 359-377. 10.1007/978-0-387-46401-5_16.View ArticleGoogle Scholar
- Sengupta M, Sharma GD, Chakraborty B: Hepatoprotective and immunomodulatory properties of Aqueous extract of Curcuma longa in carbon tetra chloride intoxicated Swiss albino mice. Asian Pac J Trop Biomed. 2011, 1 (3): 193-199. 10.1016/S2221-1691(11)60026-9.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang Q, Zhang J, Shen J, Silva A, Dennis DA, Barrow CJ: A simple 96-well microplate method for estimation of total polyphenol content in seaweeds. J Appl Phycol. 2006, 18 (3): 445-450. 10.1007/s10811-006-9048-4.View ArticleGoogle Scholar
- Jing LJ, Mohamed M, Rahmat A, Bakar MFA: Phytochemicals, antioxidant properties and anticancer investigations of the different parts of several gingers species (Boesenbergia rotunda, Boesenbergia pulchella var attenuata and Boesenbergia armeniaca). J Med Plants Res. 2010, 4 (1): 27-32.Google Scholar
- Mahmood AA, Mariod AA, Abdelwahab SI, Ismail S, Al-Bayaty F: Potential activity of ethanolic extract of Boesenbergia rotunda (L.) rhizomes extract in accelerating wound healing in rats. J Med Plants Res. 2010, 4 (15): 1570-1576.Google Scholar
- Ramaiah SK, Apte U, Mehendale HM: Diet restriction as a protective mechanism in noncancer toxicity outcomes: a review. Int J Toxicol. 2000, 19 (6): 413-424. 10.1080/109158100750058776.View ArticleGoogle Scholar
- Chilakapati J, Shankar K, Korrapati MC, Hill RA, Mehendale HM: Saturation toxicokinetics of thioacetamide: role in initiation of liver injury. Drug Metab Dispos. 2005, 33 (12): 1877-1885.PubMedGoogle Scholar
- Djordjević VB: Free radicals in cell biology. Int Rev Cytol. 2004, 237: 57-89.View ArticlePubMedGoogle Scholar
- Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, Trerotoli P, Giannelli G, Manas D, Reeves H: AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer. 2008, 8 (1): 200-10.1186/1471-2407-8-200.View ArticlePubMedPubMed CentralGoogle Scholar
- AydIn AF, Küskü-Kiraz Z, Dogru-Abbasoglu S, Güllüoglu M, Uysal M, Koçak-Toker N: Effect of carnosine against thioacetamide-induced liver cirrhosis in rat. Peptides. 2010, 31 (1): 67-71. 10.1016/j.peptides.2009.11.028.View ArticlePubMedGoogle Scholar
- Fatemi F, Allameh A, Khalafi H, Ashrafihelan J: Hepatoprotective effects of [gamma]-irradiated caraway essential oils in experimental sepsis. Appl Radiat Isot. 2010, 68 (2): 280-285. 10.1016/j.apradiso.2009.10.052.View ArticlePubMedGoogle Scholar
- Beckman KB, Ames BN: Oxidative decay of DNA. J Biol Chem. 1997, 272 (32): 19633-19636. 10.1074/jbc.272.32.19633.View ArticlePubMedGoogle Scholar
- Bruck R, Ashkenazi M, Weiss S, Goldiner I, Shapiro H, Aeed H, Genina O, Helpern Z, Pines M: Prevention of liver cirrhosis in rats by curcumin. Liver Int. 2007, 27 (3): 373-383. 10.1111/j.1478-3231.2007.01453.x.View ArticlePubMedGoogle Scholar
- Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, John S, Nelson MR: HLA-B* 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009, 41 (7): 816-819. 10.1038/ng.379.View ArticlePubMedGoogle Scholar
- Khanna D, Sethi G, Ahn KS, Pandey MK, Kunnumakkara AB, Sung B, Aggarwal A, Aggarwal BB: Natural products as a gold mine for arthritis treatment. Curr Opin Pharmacol. 2007, 7 (3): 344-351. 10.1016/j.coph.2007.03.002.View ArticlePubMedGoogle Scholar
- Plonné D, Schulze HP, Kahlert U, Meltke K, Seidolt H, Bennett AJ, Cartwright IJ, Higgins JA, Till U, Dargel R: Postnatal development of hepatocellular apolipoprotein B assembly and secretion in the rat. J Lipid Res. 2001, 42 (11): 1865-PubMedGoogle Scholar
- Alshawsh MA, Abdulla MA, Ismail S, Amin ZA: Hepatoprotective Effects of Orthosiphon stamineus Extract on Thioacetamide-Induced Liver Cirrhosis in Rats. Evidence-Based Complement Altern Med. 2011, 1-6.Google Scholar
- Kumar A: A review on hepatoprotective herbal drugs. IJRPC. 2012, 2 (1): 92-102.Google Scholar
- Sadasivan S, Latha PG, Sasikumar JM, Rajashekaran S, Shyamal S, Shine VJ: Hepatoprotective studies on Hedyotis corymbosa (L.) Lam. J Ethnopharmacol. 2006, 106 (2): 245-249. 10.1016/j.jep.2006.01.002.View ArticlePubMedGoogle Scholar
- Kim KH, Bae JH, Cha SW, Han SS, Park KH, Jeong TC: Role of metabolic activation by cytochrome P450 in thioacetamide-induced suppression of antibody response in male BALB/c mice. Toxicol Lett. 2000, 114 (1–3): 225-235.View ArticlePubMedGoogle Scholar
- Upadhyay G, Kumar A, Singh MP: Effect of silymarin on pyrogallol-and rifampicin-induced hepatotoxicity in mouse. Eur J Pharmacol. 2007, 565 (1–3): 190-201.View ArticlePubMedGoogle Scholar
- Parthasarathy VA, Chempakam B, Zachariah TJ: Chemistry of spices. 2008, UK: CAB International, 1-20.View ArticleGoogle Scholar
- Guangwei X, Rongzhu L, Wenrong X, Suhua W, Xiaowu Z, Shizhong W, Ye Z, Aschner M, Kulkarni SK, Bishnoi M: Curcumin pretreatment protects against acute acrylonitrile-induced oxidative damage in rats. Toxicology. 2010, 267 (1–3): 140-146.View ArticlePubMedGoogle Scholar
- Ahmad A, Pillai KK, Najmi AK, Ahmad SJ, Pal SN, Balani DK: Evaluation of hepatoprotective potential of jigrine post-treatment against thioacetamide induced hepatic damage. J Ethnopharmacol. 2002, 79 (1): 35-41. 10.1016/S0378-8741(01)00349-X.View ArticlePubMedGoogle Scholar
- Chilakapati J, Korrapati MC, Hill RA, Warbritton A, Latendresse JR, Mehendale HM: Toxicokinetics and toxicity of thioacetamide sulfoxide: a metabolite of thioacetamide. Toxicology. 2007, 230 (2–3): 105-116.View ArticlePubMedGoogle Scholar
- Elaziz E, Ibrahim Z, Elkattawy A: Protective effect of Curcuma longa against CCL4 induced oxidative stress and cellular degeneration in rats. Global Veterinaria. 2010, 5: 272-281.Google Scholar
- Wang H, Peng R, Kong R, Li Y: Serum glutathione S-transferase activity as an early marker of thioacetimide-induced acute hepatotoxicity in mice. Wei sheng yan jiu. 1999, 28 (3): 179-PubMedGoogle Scholar
- Li S, Yuan W, Deng G, Wang P, Yang P, Aggarwal BB: Chemical composition and product quality control of turmeric (Curcuma longa L.). Phytochemistry. 2011, 2: 28-54.Google Scholar
- Mehendale HM: Tissue repair: an important determinant of final outcome of toxicant-induced injury. Toxicol Pathol. 2005, 33 (1): 41-51. 10.1080/01926230590881808.View ArticlePubMedGoogle Scholar
- Okuyama H, Shimahara Y, Nakamura H, Araya S, Kawada N, Yamaoka Y, Yodoi J: Thioredoxin prevents thioacetamide-induced acute hepatitis. Comp Hepatol. 2004, 3 (Suppl 1): S6-10.1186/1476-5926-2-S1-S6.View ArticlePubMedPubMed CentralGoogle Scholar
- Bassiouny AR, Zaky AZ, Abdulmalek SA, Kandeel KM, Ismail A, Moftah M: Modulation of AP-endonuclease1 levels associated with hepatic cirrhosis in rat model treated with human umbilical cord blood mononuclear stem cells. Int J Clin Exp Pathol. 2011, 4 (7): 692-PubMedPubMed CentralGoogle Scholar
- Gressner AM, Weiskirchen R, Breitkopf K, Dooley S: Roles of TGF-beta in hepatic fibrosis. Front Biosci. 2002, 7 (1): d793-807. 10.2741/gressner.View ArticlePubMedGoogle Scholar
- Zaret KS, Grompe M: Generation and regeneration of cells of the liver and pancreas. Science. 2008, 322 (5907): 1490-1494. 10.1126/science.1161431.View ArticlePubMedPubMed CentralGoogle Scholar
- Gaedeke J, Noble NA, Border WA: Curcumin blocks multiple sites of the TGF-β signaling cascade in renal cells. Kidney Int. 2004, 66 (1): 112-120. 10.1111/j.1523-1755.2004.00713.x.View ArticlePubMedGoogle Scholar
- Elsharkawy A, Oakley F, Mann D: The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis. 2005, 10 (5): 927-939. 10.1007/s10495-005-1055-4.View ArticlePubMedGoogle Scholar
- Wang ME, Chen YC, Chen IS, Hsieh SC, Chen SS, Chiu CH: Curcumin protects against thioacetamide-induced hepatic fibrosis by attenuating the inflammatory response and inducing apoptosis of damaged hepatocytes. J Nutr Biochem. 2012Google Scholar
- Chen NL, Bai L, Li L, Chen PL, Zhang C, Liu CY, Deng T, Chen H, Jia KM, Zhou ZQ: Apoptosis pathway of liver cells in chronic hepatitis. World J Gastroenterology. 2004, 10 (21): 3201-3204.View ArticleGoogle Scholar
- Chen LH, Hsu CY, Weng CF: Involvement of P53 and Bax/Bad triggering apoptosis in thioacetamide-induced hepatic epithelial cells. World J Gastroenterol. 2006, 12 (32): 5175-PubMedPubMed CentralGoogle Scholar
- Sakr SA, Shalaby SY: Metiram-induced histological and histochemical alterations in Liver and kidney of pregnant mice. Life Sci J. 2012, 9 (1):
- Malhi H, Gores GJ, Lemasters JJ: Apoptosis and necrosis in the liver: a tale of two deaths?. Hepatology. 2006, 43 (S1): S31-S44. 10.1002/hep.21062.View ArticlePubMedGoogle Scholar
- Girish C, Koner BC, Jayanthi S, Ramachandra Rao K, Rajesh B, Pradhan SC: Hepatoprotective activity of picroliv, curcumin and ellagic acid compared to silymarin on paracetamol induced liver toxicity in mice. Fundam Clin Pharmacol. 2009, 23 (6): 735-745. 10.1111/j.1472-8206.2009.00722.x.View ArticlePubMedGoogle Scholar
- Organization WH: WHO monographs on selected medicinal plants. 2002, vol. 1. Geneva: World Health OrganizationGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/13/56/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.